SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production

Patients with cancer who have high serum levels of squamous cell carcinoma antigen 1 (SCCA1, now referred to as SERPINB3) commonly experience treatment resistance and have a poor prognosis. Despite being a clinical biomarker, the modulation of SERPINB3 in tumor immunity is poorly understood. We foun...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Liyun, Shi, Victoria, Wang, Songyan, Sun, Lulu, Freeman, Rebecca, Yang, Jasmine, Inkman, Matthew J., Ghosh, Subhajit, Ruiz, Fiona, Jayachandran, Kay, Huang, Yi, Luo, Jingqin, Zhang, Jin, Cosper, Pippa, Luke, Clifford J., Spina, Catherine S., Grigsby, Perry W., Schwarz, Julie K., Markovina, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378164/
https://www.ncbi.nlm.nih.gov/pubmed/37279067
http://dx.doi.org/10.1172/JCI163841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378164/
https://www.ncbi.nlm.nih.gov/pubmed/37279067
http://dx.doi.org/10.1172/JCI163841

Ejemplares similares